<SEC-DOCUMENT>0001193125-25-227565.txt : 20251002
<SEC-HEADER>0001193125-25-227565.hdr.sgml : 20251002
<ACCEPTANCE-DATETIME>20251002090412
ACCESSION NUMBER:		0001193125-25-227565
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20251002
DATE AS OF CHANGE:		20251002

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			KAZIA THERAPEUTICS LTD
		CENTRAL INDEX KEY:			0001075880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279773
		FILM NUMBER:		251367163

	BUSINESS ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000
		BUSINESS PHONE:		01161298780088

	MAIL ADDRESS:	
		ADDRESS IS A NON US LOCATION: 	YES
		STREET 1:		THREE INTERNATIONAL TOWERS LEVEL 24,
		STREET 2:		300 BARANGAROO AVENUE
		CITY:			SYDNEY NSW
		PROVINCE COUNTRY:   	C3
		ZIP:			2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NOVOGEN LTD
		DATE OF NAME CHANGE:	19981228
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d69052d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3)<BR>Registration No. 333-279773 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(to Prospectus dated
December&nbsp;2, 2024) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>1,770,000 American Depositary Shares representing </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>885,000,000 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Ordinary
Shares </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g69052g1002015433033.jpg" ALT="LOGO" STYLE="width:2.29306in;height:0.667361in;">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement is being filed to update and supplement the information contained in the prospectus dated December&nbsp;2, 2024 (the
&#8220;Prospectus&#8221;), which forms a part of our Registration Statement on Form <FONT STYLE="white-space:nowrap">F-1</FONT> (Registration <FONT STYLE="white-space:nowrap">No.&nbsp;333-279773),</FONT> with the information contained in our current
report on Form <FONT STYLE="white-space:nowrap">6-K,</FONT> furnished to the Securities and Exchange Commission on October&nbsp;2, 2025 (the &#8220;October 2, 2025 Form <FONT STYLE="white-space:nowrap">6-K&#8221;).</FONT> Accordingly, we have
attached the October&nbsp;2, 2025 Form <FONT STYLE="white-space:nowrap">6-K</FONT> to this prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus supplement updates and
supplements the information in the Prospectus and is not complete without, and may not be delivered or utilized except in combination with, the Prospectus, including any amendments or supplements thereto. This prospectus supplement should be read in
conjunction with the Prospectus and if there is any inconsistency between the information in the Prospectus and this prospectus supplement, you should rely on the information in this prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The ADSs are listed on The Nasdaq Capital Market (&#8220;Nasdaq&#8221;) under the symbol &#8220;KZIA.&#8221; On October&nbsp;1, 2025, the last reported sale
price of the ADSs on Nasdaq was $6.85 per ADS. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See &#8220;Risk Factors&#8221; beginning on
page 9 of the Prospectus and the &#8220;Risk Factors&#8221; in &#8220;Item 3. Key <FONT STYLE="white-space:nowrap">Information-D.</FONT> Risk Factors&#8221; of our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">20-F,</FONT> which
is incorporated by reference in the Prospectus, as well as in any other recently filed reports and, if any, in any applicable prospectus supplement. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
adequacy or accuracy of the Prospectus or this prospectus supplement. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The
date of this prospectus supplement is October&nbsp;2, 2025 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>Form <FONT STYLE="white-space:nowrap">6-K</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE <FONT STYLE="white-space:nowrap">13a-16</FONT> OR <FONT STYLE="white-space:nowrap">15d-16</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the month of October, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number <FONT STYLE="white-space:nowrap">000-29962</FONT> </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>Kazia Therapeutics Limited </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of registrant&#8217;s name into English) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Three International Towers Level&nbsp;24 300 Barangaroo Avenue Sydney NSW 2000 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form <FONT STYLE="white-space:nowrap">20-F</FONT> or Form <FONT
STYLE="white-space:nowrap">40-F.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form <FONT STYLE="white-space:nowrap">20-F&#8194;&#9746;&#8195;&#8195;&#8195;&#8195;Form</FONT> <FONT
STYLE="white-space:nowrap">40-F&#8194;&#9744;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form
<FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form <FONT STYLE="white-space:nowrap">6-K</FONT> in paper as permitted by Regulation <FONT
STYLE="white-space:nowrap">S-T</FONT> Rule 101(b)(7):&#8194;&#9744; </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION CONTAINED IN THIS FORM <FONT STYLE="white-space:nowrap">6-K</FONT> REPORT
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On October&nbsp;2, 2025, Kazia Therapeutics Limited (the &#8220;Company&#8221;) issued a press release titled &#8220;Kazia
Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen.&#8221; A copy of this release is attached hereto as Exhibit 99.1 and is incorporated herein by
reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby incorporates by reference the information contained herein, including Exhibit 99.1, except for the quote of
Dr.&nbsp;John Friend, Chief Executive Officer of the Company, contained in Exhibit 99.1, into the Company&#8217;s registration statement on Form <FONT STYLE="white-space:nowrap">F-3</FONT> (File
<FONT STYLE="white-space:nowrap">No.&nbsp;333-281937).</FONT></P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>EXHIBIT LIST </U></B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD WIDTH="93%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center"><B>Exhibit</B></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"><B>Description</B></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Press Release of Kazia Therapeutics Limited dated October&nbsp;2, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Limited</B> (Registrant) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">John Friend</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Chief Executive Officer</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: October&nbsp;2, 2025</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sydney, Australia &#8211; October&nbsp;2, 2025;<I> </I>Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, today
reported a substantial reduction in tumor burden from a single-patient expanded access case in triple-negative breast cancer (TNBC) treated with a combination regimen that included the Company&#8217;s investigational
<FONT STYLE="white-space:nowrap">pan-PI3K/mTOR</FONT> inhibitor, paxalisib. After three weeks of combination immunotherapy/chemotherapy plus paxalisib, imaging performed at the treating institution showed an 86% reduction in overall tumor burden.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The patient is a 40+ year old female initially diagnosed with TNBC in April 2023. She received neoadjuvant chemotherapy and immunotherapy, followed by
bilateral mastectomy six weeks post-treatment with no residual cancer detected, followed by radiation therapy. Approximately two years later, the patient was diagnosed with metastatic disease to bone and lungs. She was then treated under a
single-patient expanded-access protocol with an immunotherapy/chemotherapy regimen plus paxalisib. After three weeks of therapy, imaging demonstrated an 86% overall tumor reduction. The patient&#8217;s profile and treatment approach are highly
similar to the inclusion and combination strategy being evaluated in Kazia&#8217;s Phase 1b TNBC study, which is assessing paxalisib in combination with Keytruda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) and
chemotherapy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&#8220;Although this is a single-patient expanded-access case, the speed and magnitude of tumor regression are highly encouraging and align
with our scientific rationale for combining paxalisib with immune checkpoint blockade,&#8221; said Dr.&nbsp;John Friend, M.D., Chief Executive Officer of Kazia Therapeutics. &#8220;This experience reinforces our commitment to our ongoing, company
sponsored Phase 1b trial in advanced breast cancer, and it echoes the recent <FONT STYLE="white-space:nowrap">ex-vivo</FONT> findings showing disruption of circulating tumor cell clusters with paxalisib.&#8221; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About the ongoing Phase 1b TNBC trial </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia is
conducting a company-sponsored multi-centered Phase 1b study in Australia evaluating paxalisib in combination with Keytruda<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> and chemotherapy for advanced breast cancer, including TNBC. The
study is designed to assess safety, preliminary anti-tumor activity, and translational biomarkers, including effects on circulating tumor cells and cluster dynamics to better understand how paxalisib may enhance immunotherapy responsiveness in this
population. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>For investor and media, please contact Alex Star, Managing Director LifeSci Advisors LLC, Astarr@lifesciadvisors.com, <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">+1-201-786-8795.</FONT></FONT></FONT> </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Kazia Therapeutics </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company, based in Sydney, Australia. Our lead program is paxalisib, an
investigational brain penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of cancer. Licensed from Genentech in late 2016, paxalisib is or has been the subject of ten clinical trials in this
disease. A completed Phase 2/3 study in glioblastoma <FONT STYLE="white-space:nowrap">(GBM-Agile)</FONT> was reported in 2024 and discussions are ongoing for designing and executing a pivotal registrational study in pursuit of a standard approval.
Other clinical trials involving paxalisib are ongoing in advanced breast cancer, brain metastases, diffuse midline gliomas, and primary central nervous system lymphoma, with several of these trials having reported encouraging interim data. Paxalisib
was granted Orphan Drug Designation for glioblastoma by the U.S. Food and Drug Administration (FDA) in February 2018, and Fast Track Designation (FTD) for glioblastoma by the FDA in August 2020. Paxalisib was also granted FTD in July 2023 for the
treatment of solid tumor brain metastases harboring PI3K pathway mutations in combination with radiation therapy. In addition, paxalisib was granted Rare Pediatric Disease Designation and Orphan Drug Designation by the FDA for diffuse intrinsic
pontine glioma in August 2020, and for atypical teratoid / rhabdoid tumors in June 2022 and July 2022, respectively. Kazia is also developing EVT801, a small molecule inhibitor of VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical
data has shown EVT801 to be active against a broad range of tumor types and has provided evidence of synergy with immuno-oncology agents. A Phase I study has been completed and preliminary data was presented at 15th Biennial Ovarian Cancer Research
Symposium in September 2024. For more information, please visit www.kaziatherapeutics.com or follow us on X @KaziaTx. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement may contain forward-looking statements, which can generally be identified as such by the use of words such as &#8220;may,&#8221;
&#8220;will,&#8221; &#8220;estimate,&#8221; &#8220;future,&#8221; &#8220;forward,&#8221; &#8220;anticipate,&#8221; or other similar words. Any statement describing Kazia&#8217;s future plans, strategies, intentions, expectations, objectives, goals
or prospects, and other statements that are not historical facts, are also forward looking statements, including, but not limited to, statements regarding: the timing for results and data related to Kazia&#8217;s clinical and preclinical trials,
Kazia&#8217;s strategy and plans with respect to its paxalisib program, the potential benefits of paxalisib as an investigational PI3K/mTOR inhibitor, timing for any regulatory submissions or discussions with regulatory agencies and the potential
market opportunity for paxalisib. Such statements are based on Kazia&#8217;s current expectations and projections about future events and future trends affecting its business and are subject to certain risks and uncertainties that could cause actual
results to differ materially from those anticipated in the forward-looking statements, including risks and uncertainties associated with clinical and preclinical trials and product development, including the risk that interim or early data may not
be consistent with final data, risks related to regulatory approvals, risks related to the impact of global economic conditions, and risks related to Kazia&#8217;s ability to regain and/or maintain compliance with the applicable Nasdaq continued
listing requirements and standards. These and other risks and uncertainties are described more fully in Kazia&#8217;s Annual Report, filed on form <FONT STYLE="white-space:nowrap">20-F</FONT> with the SEC, and in subsequent filings with the United
States Securities and Exchange Commission. Kazia undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise, except as required under applicable law. You should not
place undue reliance on these forward-looking statements, which apply only as of the date of this announcement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorized for
release by Dr John Friend, CEO </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g69052g1002015433033.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g69052g1002015433033.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  _ -D# 2(  A$! Q$!_\0
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GR$8S6RO>FA1GVIPQVI,J"LA:7%)FC-(H,"EI,T9H 6DHS24 ?__9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
